NervGen Pharma ( (TSE:NGEN) ) has shared an update.
NervGen Pharma announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, where CEO Mike Kelly will present on the company’s progress. NervGen is advancing its lead molecule, NVG-291, a pioneering therapeutic peptide aimed at nervous system repair, and has received Fast Track designation from the FDA for spinal cord injury. This participation at the conference highlights NervGen’s ongoing efforts to strengthen its position in the biotech industry and engage with stakeholders.
More about NervGen Pharma
NervGen Pharma is a clinical-stage biotech company focused on developing neurorestorative therapeutics. It aims to promote nervous system repair in neurotrauma and neurologic diseases, with key products like NVG-291 targeting spinal cord injury and other neurological conditions.
YTD Price Performance: -14.91%
Average Trading Volume: 73,705
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $138.9M
See more insights into NGEN stock on TipRanks’ Stock Analysis page.